Trials / Completed
CompletedNCT00351871
Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy
Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to better understand the influence of insulin resistance upon treatment response in hepatitis C virus treated with PEG Intron and Rebetol.
Detailed description
The relationship between HCV and IR is an evolving one. This study will allow a more formal evaluation of this relationship. Four hundred patients will be treated using weight based Peg Intron and Rebetol. Clinical and biochemical data related to IR will be collected to determine if any such factors can predict who will have a sustained virological response. To evaluate patients for insulin resistance, the HOMA score (the product of the fasting insulin level and blood glucose level), waist circumference, and body mass index will be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PEG-Intron Plus REBETOL |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2006-07-13
- Last updated
- 2009-02-04
Source: ClinicalTrials.gov record NCT00351871. Inclusion in this directory is not an endorsement.